Nicolas Hulscher et al., 2026-06-01: Prospective observational cohort of 197 cancer patients prescribed compounded ivermectin 25 mg plus mebendazole 250 mg off-label through a U.S. telemedicine platform, reporting an 84.4% self-reported clinical benefit ratio at six months; the record is marked RETRACTED (notice at IVD-29).
We analyzed a prospective observational cohort of 197 patients with cancer prescribed ivermectin and mebendazole off-label via a U.S. telemedicine platform.
3243
Nicolas Hulscher et al., 2026-06-01: Prospective observational cohort of 197 cancer patients prescribed compounded ivermectin 25 mg plus mebendazole 250 mg off-label through a U.S. telemedicine platform, reporting an 84.4% self-reported clinical benefit ratio at six months; the record is marked RETRACTED (notice at IVD-29). C5. Study type: prospective observational cohort with self-reported survey outcomes; n=197 enrolled, 122 (61.9%) with 6-month follow-up. Country United States (telemedicine platform; authors at The Wellness Company and the McCullough Foundation, with Risch at Yale). Dose: compounded capsules 25 mg ivermectin + 250 mg mebendazole, dose-stratified analyses reported but the per-patient schedule is in the full text. Disease mix: prostate 27.9%, breast 18.3%. Outcomes: self-reported – CBR 84.4% (95% CI 77.0-89.8), 48.4% tumour regression or NED (32.8% NED, 15.6% regression), 36.1% stable, 15.6% progression; side effects 25.4%, mostly GI. Concurrent therapy: chemotherapy 27.9%, radiation 21.3%, surgery 19.7%, supplements 49.2%, diet 37.7%. Comparator: none (single-arm; the paper compares its CBR with chemotherapy figures from other studies). Funding/disclosures: the authors' affiliations include The Wellness Company, which supplied the prescriptions – a commercial interest the retraction notice does not itself raise but which a reader should weigh. STATUS: retracted 2026-10 – see the retraction notice row. Excerpt taken from the abstract as printed on the article PDF. Source_url is the PubMed record so the abstract can be re-checked without the publisher's bot wall; the article PDF is at https://ar.iiarjournals.org/content/anticanres/46/6/3243.full.pdf (returned 403 to an automated fetch on 2026-11-19). Also filed as IVF-17 (claims C3, C5). Study type: uncontrolled series.
